Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 mars 2025 08h33 HE | Source: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
11 mars 2025 06h00 HE | Source: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.